pharmaphorum
MARCH 2, 2022
Amazon’s encroachment into healthcare advanced a little further this week when the online giant launched a doctor consultation service delivered via its Alexa voice assistant, with the help of telehealth player Teladoc. Users of the service will be able to request non-urgent medical care around the clock, simply by telling Alexa via their Amazon Echo device that they want to speak to a doctor.
Pharma Times
MARCH 2, 2022
MS patients given boost by results of study into Kesimpta – a self-administered treatment with potential to improve lives
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
MARCH 2, 2022
Annual Drug Patent Expirations for TEKTURNA+HCT Tekturna Hct is a drug marketed by Noden Pharma and is included in one NDA. It is available from one supplier. There are two…. The post New patent expiration for Noden Pharma drug TEKTURNA HCT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MARCH 1, 2022
The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 4, 2022
With prospects of an early, accelerated approval for Roche’s Alzheimer’s disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the hope of building its case for the drug. The new placebo-controlled SKYLINE study will enrol 1,250 people aged 60 to 80 with the earliest biological signs of Alzheimer’s – in other words signs of amyloid accumulation in the central nervous system – but no cognitive impairment.
Pharma Times
MARCH 3, 2022
The phase 3 MELODY study reveals that nirsevimab vaccine reduces lower respiratory tract infections
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Channels
MARCH 4, 2022
Today’s guest post comes from Miranda Gill, Vice President of Network at CoverMyMeds. Miranda discusses how integrated technology solutions can be used at critical moments in the patient’s journey to increase access, affordability, and adherence to therapies. To learn more about CoverMyMeds’ prescription decision support tools for the entire care team, visit CoverMyMeds at HIMSS22.
pharmaphorum
FEBRUARY 28, 2022
UK Health Secretary Sajid Javid has said he wants to accelerate the rollout of electronic patient records (EPR) in the NHS, with 90% of NHS trusts using them by the end of 2023. Javid laid out the new target in a speech to the HSJ Digital Transformation Summit, in which he said that current estimates are that one in five NHS trusts still do not have EPR, and so are missing out on a key technology to deliver better, safer care for patients.
Pharma Times
MARCH 4, 2022
UKHSA reports an increase in norovirus cases throughout educational settings – particularly in nursery and childcare facilities
Outsourcing Pharma
MARCH 1, 2022
The company (which specializes in developing therapies for rare cancers) currently is working on a number of candidates, including its lead drug CPI-613.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Channels
MARCH 1, 2022
The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks.
pharmaphorum
MARCH 3, 2022
Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with the condition. The results of the EMPULSE trial showed that adults hospitalised for acute heart failure were 36% more likely to see an improvement on clinical measures – including all-cause mortality, frequency of heart failure events, time to first heart failure event, and symptoms – in the first 90 da
Pharma Times
MARCH 3, 2022
NICE document recommends Amgen’s Lumykras (sotorasib) to treat non-small-cell lung cancer
Outsourcing Pharma
FEBRUARY 28, 2022
With a specific focus on clinical trials involving treatments for rare diseases, Orphan Reach seeks to build upon the services that conventional CROs offer.
Drug Patent Watch
MARCH 4, 2022
Annual Drug Patent Expirations for YUPELRI Yupelri is a drug marketed by Mylan Ireland Ltd and is included in one NDA. It is available from one supplier. There are fifteen…. The post New patent for Mylan Ireland drug YUPELRI appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
FEBRUARY 28, 2022
A new study has suggested that the economic burden posed by rare diseases is around 10 times higher than for common “mass market” conditions. The analysis by IQVIA and pharma company Chiesi looked at the per patient, per year (PPPY) direct, indirect and mortality-related costs associated with 24 rare diseases, and compared them to 24 chronic ailments like diabetes, heart disease, arthritis and cancers.
Pharma Times
FEBRUARY 28, 2022
Unmet need among over 7000 rare diseases is being addressed in a comprehensive action plan
Pharma Marketing Network
MARCH 2, 2022
New findings from an IQVIA report show the biopharmaceutical industry is sparking with activity with an astounding 6,000 products in development and new geographical locations seeing the boom. While it was a concern that COVID-19 would slow down new ventures in the biopharmaceutical sector, the reality has been just the opposite. According to Murray Aitken, IQVIA’s Senior VP and Executive Director of the IQVIA Institute for Human Data Science, “the pandemic has accelerated biopharmac
Drug Patent Watch
MARCH 3, 2022
Annual Drug Patent Expirations for ZYNRELEF+KIT Zynrelef Kit is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Heron Theraps drug ZYNRELEF KIT appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 2, 2022
There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative to existing mental health treatments. Ben Hargreaves discovers why medical research in the area has shifted from being highly controversial to being backed by major pharma companies and venture capital. The image of psychedelic drugs within medical research is changing.
Pharma Times
FEBRUARY 28, 2022
Quviviq can be used on a long-term basis, addressing a key limitation of existing therapies
Pharma Marketing Network
MARCH 2, 2022
Tune in to this episode of the Pharma Marketing Podcast to hear a discussion with Charles Benaiah, Innovator, Founder and CEO of Watzan, Founder of ililli , and Jennifer Ginest, Digital Marketing Manager of PMN on audio and the possibilities of integrating it into your marketing strategy.
Drug Patent Watch
MARCH 3, 2022
Annual Drug Patent Expirations for LIVMARLI Livmarli is a drug marketed by Mirum and is included in one NDA. The generic ingredient in LIVMARLI is maralixibat chloride. Additional details are…. The post New patent for MIRUM drug LIVMARLI appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
FEBRUARY 28, 2022
Amryt Pharma has been handed a major blow by the FDA, after the US regulator rejected its marketing application for Oleogel-S10, its drug for rare and debilitating skin disease epidermolysis bullosa (EB). Shares in the Ireland-based rare disease specialist fell sharply after news of the complete response letter (CRL) from the FDA emerged, with the agency asking for “additional confirmatory evidence of effectiveness” for cutaneous manifestations of dystrophic and junctional EB.
Pharma Times
MARCH 2, 2022
The post-Brexit landscape has witnessed an exponential boom in life science careers
Pharma Mirror
MARCH 2, 2022
MONTGOMERY, Ala. and PRINCETON, N.J. and LONDON and BANGALORE, India, Aedesius Health, a division of AedesiusOne Ltd, and its biopharmaceutical development incubator AO BIO, which is focused on developing and commercializing neglected and needed therapies, devices, and diagnostics, today announced a comprehensive commercialization partnership with Indegene, a technology-led healthcare solutions provider.
Drug Patent Watch
MARCH 2, 2022
Annual Drug Patent Expirations for BYDUREON+PEN Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent expiration for Astrazeneca Ab drug BYDUREON PEN appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 4, 2022
The pharmaceutical industry is still picking its way through the debris of the pandemic but the gloom can be illuminated by the power of coaching to drive connections and value. It is clear that sales forces and MSL teams need to enhance their skills to make every second of their precious time in front of HCPs count. They are facing unprecedented challenge as traditional routes evaporate which means they need to be pitch perfect when they have a window of attention either in person or across dig
Pharma Times
MARCH 4, 2022
New detailed datasets will more accurately map out the impact of obesity throughout UK
Pharma Mirror
MARCH 2, 2022
Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it had reached agreement with Novartis to acquire its Ringaskiddy campus (Novartis Ringaskiddy Limited), near Cork, Ireland. Financial details of the sale, which is expected to close in Q4, 2022, have not been disclosed. Under the terms of the agreement, Sterling will acquire the 111-acre site, which includes three active pharmaceutical ingredient (API) manufacturing buildings, as well a
Drug Patent Watch
MARCH 2, 2022
Annual Drug Patent Expirations for BYDUREON Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are twenty-three patents…. The post New patent expiration for Astrazeneca Ab drug BYDUREON appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MARCH 3, 2022
DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. Under the terms of the five-year deal, Sanofi digital health apps will be integrated into Dario’s platform and Sanofi’s sales muscle will be deployed to market the combined offering.
Pharma Times
MARCH 1, 2022
Sensor development project marks the fifth joint research effort between BioMed X with Boehringer Ingelheim
Pharma Marketing Network
MARCH 2, 2022
Tune in to this episode of the Pharma Marketing Podcast to hear a discussion with Charles Benaiah, Innovator, Founder and CEO of Watzan, Founder of ililli , and Jennifer Ginest, Digital Marketing Manager of PMN on audio and the possibilities of integrating it into your marketing strategy. The post Ep. 19: Let’s Talk “TALK and Pharma” – Jennifer Ginest and Charles Benaiah, Founder of Watzan and ililli appeared first on Pharma Marketing Network.
Drug Patent Watch
MARCH 2, 2022
Annual Drug Patent Expirations for BYDUREON+BCISE Bydureon Bcise is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are fifteen…. The post New patent expiration for Astrazeneca Ab drug BYDUREON BCISE appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
134 
Let's personalize your content